Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The U.S. Meals and Drug Administration (FDA) has accepted PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to assist establish sufferers with epithelial...
AUSTIN, Texas, July 02, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Firm”), a clinical-stage pharmaceutical firm growing focused radiotherapeutics...
